Sanofi's mixed fortunes in MS drug trials has market focus on win
Releads, adds analyst comment paragraphs 1-4
By Ludwig Burger
Sept 2 (Reuters) -Sanofi's SASY.PA most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a study on a less common form of progressive MS.
Investors focused on the good news, with analysts saying the trial failure for tolebrutinib in the common relapsing form of the disease, where isolated flare-ups temporarily subside, had been widely expected as a similar compound had fallen short.
The shares jumped as much as 4.5% on Monday and were 3% higher at 0731 GMT, reaching a ten-month high.
"Despite mixed news, tolebrutinib now appears a largely de-risked perhaps $1-2 billion opportunity," Jefferies analysts said in a research note.
The French drugmaker said on Monday that two Phase III trials showed that experimental daily pill tolebrutinib was not better than its established MS drug Aubagio in reducing relapse rates in the common relapsing type of MS.
In a mitigation of the setback, Sanofi said a separate third late-stage trial showed that tolebrutinib met the main goal to treat a progressive - or steadily worsening - form of MS, which is less common, and which currently cannot be treated.
In that trial, the Sanofi drug candidate slowed disability progression when compared with a placebo, an ineffective dummy drug.
"Tolebrutinib represents an unprecedented breakthrough as a potential first-in-disease treatment option with clinically meaningful benefit in disability accumulation," said Houman Ashrafian, Sanofi's head of research & development.
The company added it would discuss those results with regulators, aiming to file for approval by the end of 2024.
Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of the Aubagio pill's patent protection, part of a push to become a powerhouse in anti-inflammatory drugs.
CEO Paul Hudson has been trying to regain investor confidence in the pharma pipeline since he unexpectedly abandoned 2025 margin targets last October to boost drug development spending.
Shares have bounced back somewhat over recent months on the strength of drug launches including Beyfortus to protect infants against a common respiratory infection.
Tolebrutinib, from the $3.7 billion takeover of Principia in 2020, belongs to a class of compounds known as Bruton's tyrosine kinase (BTK) inhibitors, which has also attracted Novartis NOVN.S, Roche ROG.S and Merck MRCG.DE.
They are designed to selectively block the harmful autoimmune reaction behind MS for a more targeted approach than standard immunosuppressant drugs.
Investors however have been kept on edge over revenue prospects because of a possible link to liver damage and uncertain efficacy.
In 2022, concerns over liver damage led to a halt in the enrolment of new patients in three of Sanofi's tolebrutinib studies that were still recruiting volunteers at the time.
On Monday, Sanofi only said liver safety was consistent with previous studies, with more data to be disclosed on Sept. 20.
Merck's BTK inhibitor last December failed to beat off-patent Aubagio on efficacy in MS trials, hitting confidence in the wider drug class.
Roche subsidiary Genentech is still in the race, but safety concerns also emerged last November. Rival Novartis has said its BTK drug candidate had shown no signs of liver damage.
Sanofi on Monday only provided a brief summary of the trials, holding off details for a medical conference in Copenhagen on Sept. 20.
Another Phase III study known as PERSEUS in another progressive form of MS is still ongoing, with results expected in 2025, Sanofi added. The French group is also working on MS candidate frexalimab in earlier development stages.
Reporting by Ludwig Burger; Editing by Marguerita Choy and Jan Harvey
Actifs liés
Dernières actualités
Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.
Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.
Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.
